Sarepta Therapeutics, Inc. Earnings

Sarepta Therapeutics, Inc.’s revenue fell -14.52% since last year same period to $399.36Mn in the Q3 2025. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated -34.65% fall in its revenue since last 3-months.

Sarepta Therapeutics, Inc.’s net profit fell -635.38% since last year same period to $-179.95Mn in the Q3 2025. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated -191.39% fall in its net profits since last 3-months.

Sarepta Therapeutics, Inc.’s net profit margin fell -726.3% since last year same period to -45.06% in the Q3 2025. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated -239.85% fall in its net profit margins since last 3-months.

Sarepta Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.05 - a -50.32% fall from last quarter’s estimates.

Sarepta Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -1.05.

Sarepta Therapeutics, Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q4 2025. This indicates that the Sarepta Therapeutics, Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.